You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

FGFR inhibition

Showing 1 - 25 of 3,032
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Urothelial Carcinoma Trial in Worldwide (Rogaratinib (BAY1163877), Atezolizumab)

Active, not recruiting
  • Urothelial Carcinoma
  • Tucson, Arizona
  • +29 more
Aug 17, 2022

Locally Advanced Gastrointestinal Stromal Tumor, Locally Advanced Sarcoma, Metastatic Gastrointestinal Stromal Tumor Trial in

Recruiting
  • Locally Advanced Gastrointestinal Stromal Tumor
  • +7 more
  • Biopsy
  • +4 more
  • Duarte, California
  • +17 more
Feb 2, 2023

Lung Cancer, NSCLC, Pulmonary Tumor Trial in Germany (ERDAFITINIB)

Unknown status
  • Lung Cancer
  • +4 more
  • Gauting, Bavaria, Germany
  • +10 more
Nov 11, 2020

Locally Advanced NSCLC, Efficacy and Safety Trial in Guangzhou (Anlotinib, Chemotherapy, Radiotherapy)

Recruiting
  • Locally Advanced Non-small Cell Lung Cancer
  • Efficacy and Safety
  • Guangzhou, Guangdong, China
    Sun yat-sen University Cancer Center
Jul 28, 2022

Cholangiocarcinoma Trial in Worldwide (Tinengotinib 8 mg, Tinengotinib 10 mg, Physician's Choice)

Not yet recruiting
  • Cholangiocarcinoma
  • Tinengotinib 8 mg
  • +2 more
  • Santa Monica, California
  • +13 more
Jul 7, 2023

Recurrent Glioblastoma, IDH-Wildtype, Recurrent WHO Grade 2 Glioma, Recurrent WHO Grade 3 Glioma Trial (Biospecimen Collection,

Not yet recruiting
  • Recurrent Glioblastoma, IDH-Wildtype
  • +2 more
  • Biospecimen Collection
  • +2 more
  • (no location specified)
May 13, 2023

Acute Myelogenous Leukemia (AML) Trial in Australia (MAX-40279)

Recruiting
  • Acute Myelogenous Leukemia (AML)
  • Darlinghurst, New South Wales, Australia
  • +3 more
Jan 18, 2022

Advanced Solid Tumor Trial in Worldwide (Erdafitinib)

Recruiting
  • Advanced Solid Tumor
  • Tucson, Arizona
  • +199 more
Jan 27, 2023

Solid Tumor, FGF Receptor Gene Mutation, FGF Amplification Trial in Tianjin (Pemigatinib)

Recruiting
  • Solid Tumor
  • +4 more
  • Tianjin, Tianjin, China
    Tianjin Medical University Second Hospital
Aug 28, 2023

Solid Tumor, Adult Trial in United States (eFT226, Sotorasib, Fulvestrant)

Recruiting
  • Solid Tumor, Adult
  • Los Angeles, California
  • +11 more
Nov 15, 2022

FGFR1 Gene Amplification, FGFR1 Gene Mutation, FGFR1 Gene Translocation Trial in United States (Pemigatinib, Quality-of-Life

Active, not recruiting
  • FGFR1 Gene Amplification
  • +18 more
  • Scottsdale, Arizona
  • +5 more
Oct 18, 2022

Cholangiocarcinoma Metastatic Trial in China (TT-00420 (tinengotinib))

Not yet recruiting
  • Cholangiocarcinoma Metastatic
  • TT-00420 (tinengotinib)
  • Guangzhou, Guangdong, China
  • +6 more
Sep 26, 2023

Recurrent ACC, metastaticACC, Unreaectable ACC Trial in Seoul (Axitinib, Observation)

Completed
  • Recurrent ACC, metastaticACC, Unreaectable ACC
  • Seoul, Korea, Republic of
    Department of Internal Medicine, Seoul National University Hospi
Mar 26, 2022

Soft Tissue Sarcoma, High Risk of Recurrence, Anlotinib Trial in Shanghai (drug, radiation, procedure)

Recruiting
  • Soft Tissue Sarcoma
  • +3 more
  • Shanghai, Shanghai, China
    Ruijin Hospital Shanghai Jiao Tong University School of Medicine
Nov 1, 2022

Advanced Malignant Solid Tumor, Cholangiocarcinoma, Metastatic Malignant Solid Tumor Trial in Columbus (Infigratinib)

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +3 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Feb 15, 2022

Renal Cell Carcinoma Trial in Iowa City (Lenvatinib, Everolimus, Partial or Radical Cytoreductive Nephrectomy)

Recruiting
  • Renal Cell Carcinoma
  • Iowa City, Iowa
    University of Iowa Hospitals and Clinics
May 4, 2022

Intrahepatic Cholangiocarcinoma Trial (derazantinib)

Available
  • Intrahepatic Cholangiocarcinoma
  • (no location specified)
Jan 13, 2023

Gastrointestinal Cancer Trial in Tianjin (Pemigatinib)

Recruiting
  • Gastrointestinal Cancer
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute & Hospital
Dec 7, 2022

Advanced Solid Tumor Trial in Beijing (ICP-192)

Recruiting
  • Advanced Solid Tumor
  • Bengbu, Anhui, China
  • +36 more
Jan 3, 2023

FGFR Gene Mutations in Tumor Tissue and Urine of Urothelial

Not yet recruiting
  • Bladder Cancer
  • FGFR test
  • (no location specified)
Apr 6, 2022

Squamous-cell NSCLC Trial in Switzerland (Rogaratinib)

Active, not recruiting
  • Squamous-cell Non-small Cell Lung Cancer
  • Baden, Switzerland
  • +10 more
Jan 20, 2022

Advanced NSCLC Trial in Jinan (almonertinib)

Recruiting
  • Advanced Non-small Cell Lung Cancer
  • Jinan, Shandong, China
    Degan Lu
Sep 12, 2023

NSCLC Trial in Suzhou (Pemigatinib)

Recruiting
  • Non-Small Cell Lung Cancer
  • Suzhou, China
    The First Affiliated Hospital of Soochow University
Jan 14, 2022

Urothelial Carcinoma Trial in Worldwide (Derazantinib dose level 1 (300mg once daily) monotherapy, Derazantinib various dose

Completed
  • Urothelial Carcinoma
  • Derazantinib dose level 1 (300mg once daily) monotherapy
  • +4 more
  • Newnan, Georgia
  • +65 more
Oct 19, 2022

Advanced NSCLC Trial in Xiamen (Pemigatinib)

Recruiting
  • Advanced Non-Small Cell Lung Cancer
  • Xiamen, Fujian, China
    the First Affiliated Hospital of Xiamen University
Mar 10, 2022